Negative Pressure Wound Therapy in Diabetic Wounds
Primary Purpose
Diabetic Foot
Status
Completed
Phase
Not Applicable
Locations
Mauritius
Study Type
Interventional
Intervention
Negative pressure wound therapy delivered through VAC
Standard of care
Sponsored by
About this trial
This is an interventional treatment trial for Diabetic Foot focused on measuring Negative pressure wound therapy, diabetic foot ulcer
Eligibility Criteria
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 18 - 75 years
- In good general health as evidenced by medical history or diagnosed with diabetes mellitus or exhibiting signs of diabetic foot ulcers
- Patients suffering from diabetic foot ulcer last more than 3 weeks
- Patients with diabetes and presence of a foot wound for more than 3 weeks
Exclusion Criteria:
- Patients under <18 years or above 75 years
- Patients unable to provide consent
- Patients suffering from chronic kidney disease or liver impairment or other chronic conditions
- Patients on anticoagulants
- Patients with non diabetic ulcers
- Patients with severe peripheral vascular disease
- Patients having contra-indication to negative pressure wound therapy
Sites / Locations
- University of Mauritius
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
Interventional arm
Control
Arm Description
NPWT will be delivered through devices (ActiVac and InfoVac) according to FDA protocol in conjunction with the polyurethane foams. Dressing changed will be on a weekly basis.
Standard of care Participants will be given the standard care provided in specialist foot care clinics or in-patients.
Outcomes
Primary Outcome Measures
Wound closure
Any wound closure or % reduction in size
Secondary Outcome Measures
Biomarkers
The amount of granulation will be determined macroscopically and microscopically through histology. Biomarkers such IL6 TNF and CD31/33 will be analysed from tissue specimens
complete wound closure
the incidence of complete closure will be determined and compared between the intervention group and the control group
Adverse events
Adverse events will include physical and psychological distress as well as infections and admissions to hospitals or recurrence of ulcer
Full Information
NCT ID
NCT05041244
First Posted
August 30, 2021
Last Updated
September 1, 2021
Sponsor
University of Mauritius
Collaborators
Ministry of Health and Wellness, Mauritius, Higher Education Commission, Mauritius, Acelity
1. Study Identification
Unique Protocol Identification Number
NCT05041244
Brief Title
Negative Pressure Wound Therapy in Diabetic Wounds
Official Title
Identification of Biomarkers, Prognostic Indicators and Development of Novel Interface Devices for the Clinical Use of Topical Negative Pressure in Diabetic Wounds
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
May 1, 2019 (Actual)
Primary Completion Date
March 1, 2021 (Actual)
Study Completion Date
July 1, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Mauritius
Collaborators
Ministry of Health and Wellness, Mauritius, Higher Education Commission, Mauritius, Acelity
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Topical Negative Pressure Wound Therapy (TNPW) is an established tool in the management of Diabetic foot ulcer in many countries. This treatment option is under utilized in the public sector of Mauritius. This study aims to determine the efficacy of TNPW through identification of biomarkers in the Mauritian setting compared with conventional treatment. Patient with DFU will be selected based on an eligible criteria and randomly assigned to intervention group or control group.
Primary Objective: To determine the efficacy of TNPW in the public sector in Mauritius Secondary Objectives: To compare healing times, prognostic factors skin biopsies based on biomarker, histological and genomic analysis A randomised controlled study is being proposed, where up to 100 participants will be recruited.
The wounds of participants in the intervention arm will be managed with 3 weeks of TNPW.
Detailed Description
Study Description: Topical Negative Pressure Wound Therapy (TNPW) is an established tool in the management of Diabetic foot ulcer in many countries. This treatment option is under utilized in the public sector of Mauritius. This study aims to determine the efficacy of TNPW through identification of biomarkers in the Mauritian setting compared with conventional treatment
Objectives:
Primary Objective: To determine the efficacy of TNPW in the public sector in Mauritius Secondary Objectives: To compare healing times, prognostic factors skin biopsies based on biomarker, histological and genomic analysis
Endpoints:
Primary Endpoint:
Incidence of complete wound closure at 7, 14 and 21 days Time for complete wound closure Side and depth of diabetic ulcer at 7, 14, 21 days Extent of granulation tissue (Epithelialisation) (7- 21 days)
Secondary Endpoints: Hospital stay, readmission, rate of amputation and rate of infections and adverse events Number of dressing changes
Study Population: 50 patients in each arm (interventional and control) Chronic diabetic ulcers, Wagner's 2-3 Male and female Diabetes Mellitus without renal and liver impairment Age 18- 74 years Stable patients with Diabetic foot ulcer A G Jeetoo Hospital, Port-Louis and Souillac District Hospital
Phase: 2 Description of Sites/Facilities Enrolling Participants: The study will take place at the above mentioned units Approval has been received by the Regional Health Director and Consultant in Charge and the Ministry of Health and Wellness for A G Jeetoo Hospital and Souillac District Hospital.
Patients will be recruited from the Diabetes Clinic or the General Surgery Department.
Patients with chronic diabetic ulcer fulfilling the eligibility criteria Description of Study Intervention: Patients will be randomized to Negative Pressure Wound Therapy (TNPW) arm and conventional treatment arm offered at the above named hospitals. TNPW devices will be used in patients in the intervention arm for 3 weeks.
TNPW is described as a medical procedure which involves application of a dressing to the wound. The dressing is attached to a vacuum device that provides sub-atmospheric pressures which help in the removal of exudates to promote the healing process. Dressings will be changed weekly.
Study Duration: 12 months Participant Duration: Each participant will be followed weekly during the procedure then 3 monthly to assess wound healing and enquire about need for further treatment including admissions and long term adverse effects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Foot
Keywords
Negative pressure wound therapy, diabetic foot ulcer
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Superiority, multi-centre randomised parallel groups
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Interventional arm
Arm Type
Experimental
Arm Description
NPWT will be delivered through devices (ActiVac and InfoVac) according to FDA protocol in conjunction with the polyurethane foams. Dressing changed will be on a weekly basis.
Arm Title
Control
Arm Type
Other
Arm Description
Standard of care Participants will be given the standard care provided in specialist foot care clinics or in-patients.
Intervention Type
Device
Intervention Name(s)
Negative pressure wound therapy delivered through VAC
Intervention Description
Initial cycle: Continuous first 48 hours Subsequent cycle: Consider intermittent DPC (5 min ON/2 mins OFF) for rest of the therapy Target Target Pressure: 50-175mmHg, to be titrated for more drainage Dressing change interval: every week; need for more frequent dressing need to be evaluated. More frequent change of adaptic can be considered. (Adaptic is a layer of thin dressing that will be in direct contact with the wound to reduce the risk of maceration and adherence to the dressing)
Intervention Type
Device
Intervention Name(s)
Standard of care
Other Intervention Name(s)
Hydrogel, foams, pad and other dressings
Intervention Description
Participants in the control arm will have their dressings changed as per the current standard of care.
Effective management of DFU will depend on accurate diagnosis and assessment and appropriate debridement of non-viable tissues in patients from both arms Patients will be advised to continue off loading and any evidence of early infection should be promptly treated.
Primary Outcome Measure Information:
Title
Wound closure
Description
Any wound closure or % reduction in size
Time Frame
3 weeks
Secondary Outcome Measure Information:
Title
Biomarkers
Description
The amount of granulation will be determined macroscopically and microscopically through histology. Biomarkers such IL6 TNF and CD31/33 will be analysed from tissue specimens
Time Frame
3 weeks
Title
complete wound closure
Description
the incidence of complete closure will be determined and compared between the intervention group and the control group
Time Frame
1 year
Title
Adverse events
Description
Adverse events will include physical and psychological distress as well as infections and admissions to hospitals or recurrence of ulcer
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged 18 - 75 years
In good general health as evidenced by medical history or diagnosed with diabetes mellitus or exhibiting signs of diabetic foot ulcers
Patients suffering from diabetic foot ulcer last more than 3 weeks
Patients with diabetes and presence of a foot wound for more than 3 weeks
Exclusion Criteria:
Patients under <18 years or above 75 years
Patients unable to provide consent
Patients suffering from chronic kidney disease or liver impairment or other chronic conditions
Patients on anticoagulants
Patients with non diabetic ulcers
Patients with severe peripheral vascular disease
Patients having contra-indication to negative pressure wound therapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Abha Jodheea-Jutton, MBBS MRCGP
Organizational Affiliation
University of Mauritius
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Mauritius
City
Le Réduit
State/Province
Moka
ZIP/Postal Code
80837
Country
Mauritius
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
All IPD has been stored in digital format in anonymised way and might be shared with other researchers on request. The request will be considered by the members of the team.
Learn more about this trial
Negative Pressure Wound Therapy in Diabetic Wounds
We'll reach out to this number within 24 hrs